Clinical Trials on GBAT+Engagement Booster in South Africa

Total 29 results

University of Witwatersrand, South Africa

Unknown

Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine (MV/VV/Hep-AV)

Measles | Hepatitis A | Varicella

South Africa
University of Sydney

Completed

Herpes Zoster Vaccine for Bone Marrow Transplant Donors (VZV-Zostavax)

Herpes Zoster

Australia
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults

Herpes Zoster

Australia
Novartis

Completed

Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection

Herpes Zoster | Chickenpox

United States, Costa Rica, Guatemala, Panama
Dynavax Technologies Corporation

Completed

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

Herpes Zoster | Vaccine-Preventable Diseases | Shingles

Australia
Vanderbilt University Medical Center
Patient-Centered Outcomes Research Institute; University of Alabama at Birmingham

Active, not recruiting

Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care (C3FIT)

Stroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke Hemorrhagic

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

Herpes Zoster

United States
GlaxoSmithKline

Completed

Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

Herpes Zoster

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

Herpes Zoster

United States, Germany, Estonia, Canada
GlaxoSmithKline

Completed

Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

Herpes Zoster

United States
GlaxoSmithKline

Completed

Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

Herpes Zoster | Herpes Zoster Vaccine

United States, Australia, Spain, Finland, Germany, Japan, Taiwan, Canada, Sweden, Korea, Republic of, Czechia, Hong Kong, Mexico, Italy, Brazil, Estonia, France, United Kingdom
GlaxoSmithKline

Completed

Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

Herpes Zoster

United States, Australia, France, Spain, Finland, Estonia, Russian Federation, Taiwan, Belgium, Korea, Republic of, Czechia, Germany, Hong Kong, Israel, Turkey, United Kingdom, Greece, Romania, Netherlands, Italy, South Africa, Ca... and more
GlaxoSmithKline

Completed

A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022

Herpes Zoster

United States, Australia, Germany, Spain, Japan, Taiwan, Sweden, Korea, Republic of, Hong Kong, Mexico, Canada, France, Italy, Brazil, Estonia, United Kingdom, Czechia, Finland
Merck Sharp & Dohme LLC

Completed

Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)

Varicella

United States
Procter and Gamble

Completed

Study of Oral PG-116800 Following a Heart Attack

Myocardial Infarction | Heart Failure | Heart Enlargement

United States, Canada, Poland
GlaxoSmithKline

Completed

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

Herpes Zoster

United States, Australia, Spain, Finland, Germany, Japan, Taiwan, Sweden, Korea, Republic of, Brazil, Mexico, Canada, Italy, France, Czechia, Estonia, Hong Kong, United Kingdom
GlaxoSmithKline

Completed

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

Herpes Zoster

United States, Australia, Spain, Finland, Germany, Japan, Taiwan, Canada, Sweden, Korea, Republic of, Czechia, Hong Kong, Mexico, Italy, Brazil, Estonia, France, United Kingdom
GlaxoSmithKline
IQVIA, USA

Active, not recruiting

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Chickenpox

Taiwan, Poland, United States, Estonia, Puerto Rico, Mexico
GlaxoSmithKline

Active, not recruiting

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

Herpes Zoster

United States, Australia, Finland, Germany, Japan, Taiwan, Sweden, Spain, Korea, Republic of, Brazil, Mexico, Italy, Canada, Czechia, Estonia, France, Hong Kong, United Kingdom
Erasmus Medical Center
Leiden University Medical Center; Medical Center Haaglanden; Rijnstate Hospital; Maasstadziekenhu... and other collaborators

Recruiting

HIV Indicator Diseases in Hospital and Primary Care (#AwareHIV)

HIV Infections | Acquired Immunodeficiency Syndrome | Sexually Transmitted Diseases, Viral | Pneumonia | Psoriasis | Weight Loss | Thrombocytopenia | Leukopenia | Dermatitis, Seborrheic | Herpes Zoster | Lymphadenopathy | Uterine Cervical Dysplasia | Primary Health Care | Diarrhea Chronic | Candida Infection | Infectious... and other conditions

Netherlands
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

Herpes Zoster

United States
GlaxoSmithKline

Completed

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

Herpes Zoster

United States, Australia, Germany, Spain, Finland, Japan, Taiwan, Sweden, Korea, Republic of, Hong Kong, Mexico, Canada, Italy, France, Brazil, Estonia, United Kingdom, Czechia
GlaxoSmithKline

Completed

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

Herpes Zoster

France, Spain, Taiwan, Belgium, Singapore, United States, Hong Kong, Russian Federation, Finland, Korea, Republic of, Czechia, Australia, Canada, Sweden, Poland, United Kingdom, Panama, Italy, Turkey, Pakistan, New Zealand
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

Measles | Rubella | Mumps | Varicella

United States
SerenaGroup, Inc.
Kinetic Concepts, Inc.

Terminated

Clinical Trial to Evaluate Blister Graft Utilizing a Novel Harvesting Device for Treatment of Venous Leg Ulcers (Cellutome)

Venous Insufficiency of Leg | Impaired Wound Healing | Diabetic Ulcers

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States, Chile
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States, Puerto Rico
GlaxoSmithKline

Completed

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

Hepatitis A

United States
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

Measles; Mumps; Rubella; Chickenpox

United States, Taiwan, Spain, Argentina, Turkey, Colombia, Puerto Rico, Latvia, Chile

Clinical Trials on GBAT+Engagement Booster in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations